DRESS syndrome associated with carbamazepine and phenytoin.
Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome reflects a serious hypersensitivity reaction to drugs. Its clinical manifestations include diffuse maculopapular rash, exfoliative dermatitis, facial edema, lymphadenopathy, fever, multivisceral involvement and it is associated with a high mortality rate. We report a 62-year-old patient suffering from epilepsia presenting erythroderma following carbamazepine intake. Blood tests revealed eosinophilia, leukocytosis, elevated liver enzymes and high levels of Eosinophil Cationic Protein (ECP). We applied systemic steroids and anticonvulsant therapy was switched to phenytoin, which had been taken previously without adverse reactions. The skin eruptions persisted and the patient developed fever. Anticonvulsant medication was discontinued and skin eruptions finally resolved under steroid application. This case report demonstrates that cross reactivity between carbamazepine and phenytoin may not only lead to the development but also to the worsening of DRESS syndrome. ECP blood levels may represent a sufficient parameter to monitor the development of DRESS syndrome.
Allam
Jean-Pierre
JP
Department of Dermatology, Friedrich-Wilhelms-University, Sigmund-Freud-Str. 25 D-53105 Bonn, Germany.
Paus
Teresa
T
Reichel
Christoph
C
Bieber
Thomas
T
Novak
Natalija
N
D000927:Anticonvulsants / Q000009:adverse effects*; D001774:Blood Chemical Analysis; D002220:Carbamazepine / Q000009:adverse effects*; D003937:Diagnosis, Differential; D003875:Drug Eruptions / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology; D004827:Epilepsy / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010672:Phenytoin / Q000009:adverse effects*
D000927:Anticonvulsants; D002220:Carbamazepine; D010672:Phenytoin